Last reviewed · How we verify
NCT05790512
Association of Oral Helicobacter Pylori Infection With Gastric Helicobacter Pylori Infection
trial in Helicobacter Pylori in 500 participants. Completed in 1 August 2023.
1 August 2023
Quick facts
| Lead sponsor | Xijing Hospital of Digestive Diseases |
|---|---|
| Status | Completed |
| Study type | OBSERVATIONAL |
| Enrollment | 500 |
| Start date | 22 November 2022 |
| Primary completion | 1 August 2023 |
| Estimated completion | 1 August 2023 |
| Sites | 1 location across China |
Conditions studied
- Helicobacter Pylori — all drugs for Helicobacter Pylori →
Sponsor
Xijing Hospital of Digestive Diseases
Who can join
Adults 18 to 70, any sex, with Helicobacter Pylori. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The aim of this study was to investigate the association between oral Helicobacter pylori infection and gastric Helicobacter pylori infection. Patients who were tested for gastric Helicobacter pylori were tested for oral Helicobacter pylori at the same time, and were divided into four groups according to the test results to compare the positive rate of oral Helicobacter pylori.
Publications & conference data
No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.
Verify or expand the search:
- PubMed search for NCT05790512
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Helicobacter Pylori
Currently open trials in the same condition.
- NCT07232095 — 7-Day Vonoprazan, High-Dose Amoxicillin, and Bismuth Therapy · Phase 4 · recruiting
- NCT07253948 — Distribution Characteristics of Helicobacter Pylori · recruiting
- NCT06943781 — Prospective Gastric Cancer Screening Using Helicobacter Pylori High-Risk Single Nucleotide Polymorphism Detection · recruiting
- NCT06871579 — Study of the Esophageal String Test (EST) for the Diagnosis of Helicobacter Pylori · NA · recruiting
- NCT07122024 — Efficacy and Safety of Keverprazan-amoxicillin Dual Therapy for Helicobacter Pylori First-line Treatment · Phase 4 · recruiting
Other Xijing Hospital of Digestive Diseases trials
Trials by the same sponsor.
- NCT07401303 — Full-time RDI for ESD: Impact on Major Adverse Events and Procedure Time · NA · not yet recruiting
- NCT07296458 — FIREFLY Trial: Fenofibrate Intervention---Randomized Evaluation in First-Line PBC Therapy · Phase 3 · recruiting
- NCT07129460 — Efficacy and Safety of Berberine for Gastric Intestinal Metaplasia · Phase 4 · not yet recruiting
- NCT07182890 — Efficacy of Clostridium Butyricum in Alleviating Anxiety and Depression in Patients With Functional Dyspepsia · Phase 4 · recruiting
- NCT07187492 — Efficacy of Bacillus Coagulans in Alleviating Anxiety and Depression in Patients With Functional Dyspepsia · Phase 4 · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT05790512 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Xijing Hospital of Digestive Diseases
- Last refreshed: 4 August 2023
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05790512.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing